Date: Wednesday, March 3, 2021
Time: 10:00 AM – 12:00 PM
Location: Zoom

Members Present:
1. Thea Brabb, Comparative Medicine (Animal Containment Expert)
2. Lesley Colby, Comparative Medicine (Animal Containment Expert)
3. Lesley Decker, Environmental Health & Safety (Biosafety Officer)
4. Richard Grant, Washington National Primate Research Center
5. Garry Hamilton (Community Member)
6. Kevin Hybiske, Allergy and Infectious Diseases
7. Stephen Libby, Laboratory Medicine (IBC Chair)
8. Susan Parazzoli (Community Member)
9. Jason Smith, Microbiology (IBC Vice Chair)
10. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 a.m. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **SUBCOMMITTEE REPORTS:**

   a. Englund, Janet, new, *A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate The Safety, Tolerability, And Immunogenicity Of A Sars-Cov-2 Rna Vaccine Candidate (Bnt162b2) Against Covid-19 In Healthy Pregnant Women 18 Years Of Age And Older*
   - Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   - This study will describe the safety of BNT162b2 (Pfizer) in pregnant women and their infants. This vaccine is already approved for use in adolescents over 16 and adults under an EUA by FDA. This study will also assess the immunogenicity of BNT162b2 in pregnant women, the transfer of antibody to their infants, and the kinetics of antibody transfer in the infant.
   - The greatest biohazardous risk is potential percutaneous exposure to staff preparing or administering the vaccine.
   - The draft BUA letter was shown. BUAL edits are needed.
   - A member made a motion to approve the draft BUA letter for Dr. Englund pending edits to the BUA letter. Another member seconded the motion.
   - **The Committee voted unanimously to approve the draft BUA for Dr. Englund pending edits to the BUA letter.**

   b. Mitchell, Patrick, new, *Evolutionary, genetic, and molecular basis of host-pathogen interactions*
   - Four members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   - The PI studies host-pathogen interactions. Studies will include transient expression of genes of interest, including genes of human, non-human primate, and microbial origin, which will be conducted in human, non-human primate, and other immortalized cell lines and microbes.
   - Work includes use of Shigella flexneri and Dengue virus in mice as well as several viral vectors, viruses, and bacteria at BSL-1 and -2.
   - A successful lab inspection has been completed.
   - All of the required trainings have been completed.
   - The IACUC protocol has not yet been submitted. In vivo approval will be sent once the protocol has been reviewed by the biosafety officer.
   - The draft BUA letter was shown. Only in vitro approval is listed on the current letter being sent at this time.
   - A member made a motion to approve the draft BUA letter for Dr. Mitchell. Another member seconded the motion.
   - **The Committee voted unanimously to approve the draft BUA for Dr. Mitchell.**
4. **ISSUES FROM THE FLOOR & PUBLIC COMMENTS:** There were no issues from the floor, and no public comments.

5. **MEETING ADJOURNED AT APPROXIMATELY 10:40 A.M.**